

Resident and Fellows

Poster Submission Rules & Format Guidelines



2018 Midyear Clinical Meeting & Exhibition
Anaheim Convention Center
Anaheim, CA
December 2-6, 2018



Educational Services Division
American Society of Health-System Pharmacists
4500 East-West Highway
Bethesda, Maryland 20814
posters@ashp.org

©2018 American Society of Health-System Pharmacists, Inc.
ASHP® is a service mark of the
American Society of Health-System Pharmacists, Inc.; registered in the U.S. Patent and Trademark Office.

2018 Residents & Fellows Poster Submission Rules & Format Guidelines

TABLE OF CONTENTS

Deadline..... 3

Authorship 4

Tasks to Complete Your Poster Abstract Online 5

Task 1 Poster Abstract Submission..... 6

Task 2 Primary Author..... 7

Task 3 Primary Author Affirmation 7

Residency Information 8

Finding Your Residency Code..... 8

Fellowship Information 8

Task 4 Co-Authors 8

Task 5 Financial Relationship Disclosure 8

Task 6 Conflict of Interest Agreement..... 8

Confirmation & Submission Number 9

Notification Information..... 9

Contact Information 9

Meeting Registrations and Cancellations 10

Sample Abstracts

Descriptive Report..... 11

Evaluative Report 12

Research-in-Progress Report..... 13

Case Report 14

2018 Residents & Fellows Poster Submission Rules & Format Guidelines

DEADLINE: 11:59 p.m. PACIFIC – October 1, 2018

To submit your abstract, visit: <https://www.ashp.org/Meetings-and-Events/Get-Involved-in-a-Meeting/Midyear-Clinical-Meeting-and-Exhibition/MCM18-Poster-Information>

Thank you for your interest in presenting at the 2018 ASHP Midyear Clinical Meeting to be held in Anaheim, CA, December 2-6, 2018.

This document is to assist you in the preparation of your abstract submission for a poster presentation. To ensure your abstract is accepted for presentation, please **read all the instructions carefully**. **Note that instructions have changed for this year.**

Important Information:

Deadline is October 1, 2018, 11:59 p.m. (Pacific). No exceptions.

This deadline is final! You may edit a submission any time prior to the deadline. No new submissions or edits will be accepted after the deadlines. ASHP will **not** edit abstracts. Incomplete submissions found after the deadline will be deleted.

❖ **Fellows:**

- You must fill out the Fellowship Program Information
- **Name of Fellowship Program**
- **State** where your fellowship occurs
- **Fellows Posters will be presented in one of the Professional Poster Sessions on Sunday or Tuesday.**

❖ **Residents**

- You must fill out your Residency Information
- **Name of Residency site**
- **State** where your residency occurs
- **Residency Code** – for ASHP accredited or accreditation-pending programs
- **Type of Residency** – e.g., PGY1 community, managed care, pharmacy, etc.
- **Resident Posters will be presented on Sunday and Wednesday.** Session times will be decided after the submission site closes and will be dependent on the number of abstracts received. Posters will be grouped by state, but not necessarily in alphabetical order. We cannot take special requests for dates or times.

❖ Sessions will begin at 8 am and could run until 5 pm. ***Please plan your travel accordingly.***

❖ **Incomplete submissions will not be considered.**

Poster Types

Your abstract content and word limits are determined by the type of poster. Poster abstracts are classified as one the following:

- **D = Descriptive Reports:** Describes new, improved or innovative roles or services in pharmacy practice, or unusual clinical cases in one or a few patients that have not been formally evaluated but are of such importance that they must be brought to the attention of practitioners. Descriptive reports must contain detailed rationale of the project or case, and the importance of the report to pharmacy practice. ([Example on page 10](#))
- **E = Evaluative Study Reports:** Describes original research, including clinical research on drug effects in humans, drug-use evaluations, and evaluations of innovative pharmacy services. Evaluative study reports must include scientific results and/or data to support the conclusions, and indicate that all clinical research represented in the abstract was approved by the appropriate ethics committee or institutional review board, and if appropriate, informed consent was obtained for all subjects. ([Example on page 11](#))
- **R = Research-in-Progress Report:** *Definition:* Uncompleted original research, including clinical research on drug effects in humans, drug-use evaluations, and evaluations of innovative pharmacy services currently in progress. **Please note:** Results can be presented on your poster at the meeting. ([Example on page 12](#))
- **C = Case Reports:** Describes an unusual *patient-specific* case that was not part of a study but the findings are of interest to clinical pharmacists. Case Reports do not need the headings Purpose, Methods, Results, or Conclusions but cannot be a research-in-progress. ([Example on page 13](#))

Authorship

PRIMARY AUTHORS

The person entering the information online **must be the Primary Author** and will be responsible for providing the required information for **all** authors. We define the "Primary Author" as the leading author of the abstract and the one whose name appears first on the abstract.

Therefore, the submitting author's name will *automatically* appear first on the citation and the abstract, and it is their contact information that will be printed on the published version of the abstract.

A Primary Author may submit only one abstract; however, they may be an additional author on other abstracts. Any Primary Author trying to submit more than one abstract will risk having ALL of their submissions rejected. Multiple abstracts on the same topic from one author or institution will not be accepted.

ADDITIONAL AUTHORS

Each submission may have up to **five (5) authors** – the Primary Author and **four (4) additional authors**. If you submit more than four additional authors ASHP will accept the first four and delete the rest. The Primary Author should check to make sure that all authors and their information are included and in the order they will appear on the abstract and citation. **ASHP will not add “forgotten” authors or make changes to the author order. Incomplete additional author information may cause the abstract to be rejected.**

TASKS to Complete for Your Abstract Proposal Online

NEW SUBMISSION PROCESS

Our new online submission tool requires the Primary Author to complete six (6) tasks to submit their poster. Some of our guidelines have changed, therefore, it is important that the Primary Author carefully read the information on the screen and follow the submission guidelines.

LOGIN – EMAIL ADDRESS & ACCESS KEY

To submit an abstract, you must create a profile which includes your name, email address, and your access key.

- The email address and the access key you created is now your login information for the poster site.

The email that is used for logging into the ASHP Poster Abstract Submission site must belong to the Primary Author – not an assistant or colleague.

You must click “Continue” button on every screen in order to save your information

Do not delete or alter the email address that is shown on your profile. Deleting the email address on this screen will cause your submission to be incomplete will not be included in the review process.

POSTER ABSTRACT TITLE

Be sure your title accurately and concisely reflects the abstract content. Submission with titles that are NOT in the correct format will be rejected. **IMPORTANT: Only put the title of the abstract in the title field. DO NOT put it in the abstract content field.**

- **Title Format**
 - Please use sentence case to format your titles. Titles in all uppercase or lowercase letters will not be accepted.
 - **Do NOT** use proprietary (brand) names in the title
 - Use Capitalized letters only for acronyms or proper nouns (e.g. countries, etc.).
 - Do not use “A,” “An,” or “The” as the first word in the title
- **Title Format Examples**
 - Incorrect:** IMPLEMENTATION OF COMPUTERIZED PRESCRIBER ORDER ENTRY (CPOE) IN A SURGICAL UNIT: ONE YEAR LATER
 - Incorrect:** implementation of computerized prescriber order entry (CPOE) in a surgical unit: One year later.
 - CORRECT:** Implementation of computerized prescriber order entry (CPOE) in a surgical unit: one year later



TASK 1: Poster Abstract Submission

Enter your poster abstract content details. Only completed submissions will be included in the reviewer process.

SUBMISSION CATEGORY

Select one category from the dropdown that appropriately reflects the content of the abstract.

Submission Categories:

- Administrative Practice/ Management /Financial Management / Human Resources
- Ambulatory Care
- Cardiology/ Anticoagulation
- Chronic/Managed Care
- Clinical Services Management
- Clinical Topics/Therapeutics
- Complementary Alternative Medicine (Herbals, etc.)
- Critical Care
- Drug Information/ Drug-Use Evaluation
- Emergency Medicine
- Emergency Preparedness
- Geriatrics
- Home Care
- Infectious Diseases/HIV
- Informatics/Technology/Automation
- Investigational Drugs
- I.V. Therapy/ Infusion Devices
- Leadership Development
- Nuclear Pharmacy
- Nutrition Support
- Oncology/Hematology
- Operating Room Pharmacy
- Pain Management/ Palliative Care
- Pediatrics
- Pharmacokinetics
- Pharmacy Law/ Regulatory/ Accreditation
- Pharmacy Technicians: Competencies Development/Other
- Precepting/Preceptor Skills/Education and Training
- Professionalism and Career Development
- Psychiatry/Neurology
- Safety/Quality
- Small and/or Rural Practice
- Toxicology
- Transplant/Immunology
- Women's Health

ABSTRACT FORMAT:

- **Correctly** format your title. (see page 5 for details on correct title format)
- **Word Limits** – your entire abstract should be approximately 400 - 625 words (**including the poster title**) for a Descriptive Report, Evaluative Study, & Case Report. Research-in-Progress word limit should be 325 words total.
- **Do not** use special functions such as tabs, underlines, trademarks, superscript, subscript, bold, or italics.
- **Spell out** special symbols - Greek letters, degrees, plus and/or minus signs, greater than or less signs, percentage, etc. Use standard abbreviations.
- **Do not include** graphs, tables, or illustrations in your abstract.
- Spell out all pharmaceutical **acronyms**.
- Do not include the title or authors in the body of the abstract.
- **Abstracts in outline form will be rejected.**
- **Submission Type** – Your abstract must be a Descriptive, Evaluative Study Report, Research-in-Progress-Report, or Case Report.

WORD LIMITS

Your abstract must follow the designated word limits for your specific poster type:

Submission Types	Evaluative Study (625 words)	Descriptive Report (625 words)	Research-in-Progress (325 words)	Case Reports (625 words)
Title	25 words	25 words	25 words	25 words
Purpose	100 words	100 words	100 words	600 words
Methods	200 words	200 words	200 words	N/A
Results	200 words	200 words	N/A	N/A
Conclusion	100 words	100 words	N/A	N/A

NOTE: If your abstract is accepted, the presentation must not differ from the originally accepted title and abstract content.

TASK 2: PRIMARY AUTHOR

PRIMARY AUTHOR

To complete this task, click on the Primary Author's name to update the required fields. The required information includes:

- First, Middle initial, Last names, mailing address, contact information (*i.e.*, phone and email address).
- Professional information, *i.e.*, position/title, employer, and credentials

You must enter this information to update your profile after you created your access key. Click the Continue button to save your changes. Click - Save the Primary Author button to move to the next task.

- ❖ Do not use ALL CAPS
- ❖ Remember to include a period after your middle initial
- ❖ Do not place degrees in the "Last Name" field; add degrees in the credentials field

TASK 3: PRIMARY AUTHOR AFFIRMATION

Affirmation of Content – The Primary Author must affirm the content of the submission on behalf of all authors listed on the abstract. Affirmation indicates that all co-authors are aware of the content and an author, preferably the Primary Author, will present the poster during the time assigned if the abstract submission is accepted. **This abstract has NOT been presented or published previously. Exceptions are those presented at a state society meeting or an international meeting held outside the U.S.**

Other items include:

- ASHP Membership
- Any Federal affiliation
- Residency or Fellowship affiliation

Residency Information

Due to space limitations, only submissions from residents participating in ASHP Accredited or Accreditation-Pending PGY1 or PGY2 programs (Pre-candidate and candidate) will be accepted. If you do not know your residency program's code, search for it online.

Finding Your Residency Code

Access ASHP Residency Directory online to search for your residency code at:
<https://accred.ashp.org/aps/pages/directory/residencyProgramSearch.aspx>

- Click the link to the Online Residency Directory
- Enter the state of your residency, zip code, or Institution Name – click Search
- The residency code will appear next to the name of the residency site and type of residency

You must fill out your Residency Information:

- Name of Residency site
- State (or Country) -where your residency occurs
- Residency Code – for ASHP accredited or accreditation-pending programs

Fellowship Information

Fellows: You must fill out the Fellowship Program Information only.

- **Name of Fellowship Program**
- **State (or Country)** -where your fellowship occurs

TASK 4: CO-AUTHORS

Additional Authors / Co-Authors – Each submission may have to up to five (5) authors, the Primary Author and four (4) additional authors. The Primary Author:

- Must submit the names and email addresses using the Co-Author task.
- Is responsible for ensuring all authors are included and in the order they will appear on the abstract, citation, and on the poster display.
- ASHP will not add “forgotten” authors or make changes to the order of the authors.

TASK 5: FINANCIAL RELATIONSHIP DISCLOSURE

Disclosures – Only the Primary Author will complete the potential conflict of interest information for themselves.

- Click on the Primary Author’s name (your name) to complete the required information. For this task.
- Disclose any financial relationships for you and/or your spouse
- Type your name to certify the information is correct to complete the form and move to the next task.

TASK 6: CONFLICT OF INTEREST AGREEMENT

The Primary Author must complete and sign the conflict of interest agreement terms for their submission. This includes agreeing to display the disclosures on the poster display. Primary Author must:

- ❖ Read and sign the agreement
- ❖ Click Submit Agreement button to complete the task.

CONFIRMATION & SUBMISSION NUMBER

When all the submission tasks are completed (showing a green check mark) you must save your submission before you can submit it. Click the **Save Submission** button and the screen will show a summary of your submission. It will also indicate that you have completed all the required tasks for your abstract proposal.

- ❖ Click the **Submit** button to submit the abstract.
- ❖ You will automatically get a confirmation email with your submission details. Please save it for your records.
- ❖ Your abstract title will appear on the screen with a link to preview the content or send a confirmation email.

Submission Number: Your Proposal ID is your Submission Number. It appears on the screen with the list of tasks you completed as well as in your email confirmation.

Note: *If you login later to edit a completed abstract, clicking "Save" will only give you the option to preview the abstract or resend your email confirmation. Any updates will automatically be included if the abstract status is showing complete.*

INCOMPLETE SUBMISSIONS

Incomplete submissions will be deleted from our online system (i.e. missing required elements, etc.)

NOTIFICATION INFORMATION

NOTIFICATIONS

- ❖ **Fellows will be notified by email as to their acceptance and presentation date/time.**
- ❖ **A Resident Poster acceptance list by Primary Author Last Name will be posted in mid-October (~ October 21) at:** <https://www.ashp.org/Meetings-and-Events/Get-Involved-in-a-Meeting/Midyear-Clinical-Meeting-and-Exhibition/MCM18-Poster-Information>. If your submission is accepted, we encourage you to read the Poster Presenter Handbook, which will also be posted online.

CONTACT INFORMATION

CONTACT US

If you have questions regarding your submission, please send an email to posters@ashp.org. Please include your name, the title of the submission and your **Submission Number**. ASHP will only provide information about the abstract to the Primary Author.

MEETING REGISTRATIONS AND CANCELLATIONS

MEETING REGISTRATION

Presenting a poster at our meeting is a voluntary effort and ASHP cannot pay expenses for your participation. If your submission is accepted you, are responsible for your own meeting registration fee and travel. **All presenters must be registered for the meeting**, at least for the day of your poster presentation.

WITHDRAWALS/CANCELLATIONS

Written notification is required for all submission withdrawals. Only the Primary Author may withdraw a submission. Send your withdrawal request to posters@ashp.org. Please include your name, the title of the submission, and your submission number.

Please note: The Resident poster acceptance listing will be posted online mid-October (~ October 21st). Withdrawal requests must be received via email before this date or we **cannot guarantee that your presentation citation** and/or abstract will not appear in print, on the ASHP Website, or in electronic media.

SAMPLE ABSTRACTS

DESCRIPTIVE REPORT POSTER ABSTRACT SAMPLE

PLEASE NOTE: Do not include the field names – Purpose, Methods, Results*, and Conclusion* – in the body of your abstract. Details may be excluded in Student abstracts.

Title: Assessing pharmacist competency for processing adult chemotherapy orders in a community hospital

Purpose: The avoidance of errors in the processing of chemotherapy orders is an important component in the pharmacy department's medication-use safety initiatives. Chemotherapy order processing was identified as a needed competency assessment to heighten awareness in recognizing and preventing chemotherapy medication errors. This project was designed to uncover and correct gaps in the knowledge that pharmacists needed for the safe processing of chemotherapy orders at a community hospital.

Methods: A pharmacist with advanced training (specialty residency) in oncology wrote a certification module and a competency assessment examination. The certification module included readings, the hospital policy on processing chemotherapy orders, and a chemotherapy order-processing checklist designed for the pharmacist. The assessment examination used three actual patient chemotherapy orders, each with specific patient demographics, laboratory values, and imbedded errors. Pharmacists taking the examination needed to identify the errors to process the orders safely. All staff pharmacists were required to complete the examination and instructed to work independently. A score of 100 percent was required to pass the competency assessment.

Results: Twelve pharmacists completed the module. Seven pharmacists correctly identified all the medication order errors in the competency assessment examination. Five pharmacists needed additional training in their identified areas of deficiency and took a customized assessment examination to address those areas specifically. All five pharmacists successfully completed the second assessment examination. The pharmacy director and clinical coordinators felt that the competency assessment examination was successful in identifying gaps in knowledge. The pharmacists indicated that they were more confident processing chemotherapy orders after successful completion of the module and competency assessment.

Conclusion: Competency assessment was helpful in identifying and correcting knowledge gaps and may be useful in medication order processing of high risk medications as part of the pharmacy department medication-use safety plan.

EVALUATIVE STUDY ABSTRACT SAMPLE

PLEASE NOTE: Do not include the field names – Purpose, Methods, Results, and Conclusion – in the body of your abstract.

Title: Effect of carvedilol or atenolol combined with a renin-angiotensin blocker on glycemic control

Purpose: Beta-blockers decrease cardiovascular risk in patients with hypertension and diabetes mellitus (DM). However, their use has been associated with increased fasting glucose and HbA1c levels in these patients. The purpose of this study was to determine whether carvedilol or atenolol had more favorable glycemic effects on patients with diabetes and hypertension who were also using a renin-angiotensin (RAS) blocker, which is known to improve glycemic control.

Methods: The institutional review board approved this open-label, randomized, and controlled group study. Men and women aged 18-65 provided informed consent and enrolled if they had Type 2 DM and stage 1 or 2 hypertension controlled by medication. Patients taking a non-ocular beta-blocker within the past 3 months and those with pulmonary, cardiovascular, or kidney disease were excluded. Antihypertensive treatment must have included an RAS blocker, such as an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB). Following a washout period to discontinue all other antihypertensive treatments, 48 patients were randomized to receive either carvedilol (n equals 25) or atenolol (n equals 23) for 24 weeks. Study medication was titrated from carvedilol 6.25 mg twice daily and atenolol 12.5 mg twice daily to a maximum dose of 25 mg and 100 mg twice daily, respectively, at two-week intervals toward target blood pressure levels (less than or equal to 130/80 mmHg). The primary outcome measure was a change from baseline in HbA1c after 6 months of treatment. Secondary outcomes included changes in blood pressure and heart rate. It was determined that 23 participants per treatment group would yield 80 percent power to detect a difference of 0.20 percent between groups for the primary outcome. Data are expressed as means with 95 percent confidence intervals, and evaluation of primary and secondary outcomes utilized analysis of variance.

Results: The mean difference between carvedilol and atenolol in the change in HbA1c from baseline was 0.21 percent (95 percent CI, 0.04 percent to 0.27 percent, P equals 0.004). HbA1c levels increased with atenolol administration (0.23 percent; 95 percent CI, 0.08 percent to 0.31 percent, P less than 0.001) but did not change significantly with carvedilol (0.02 percent; 95 percent CI, -0.06 to 0.08 percent, P equals 0.65). Effects on blood pressure and heart rate were comparable.

Conclusions: Use of carvedilol in the presence of RAS blockade did not affect glycemic control. However, atenolol was associated with a slight increase in HbA1c after 6 months of treatment. The clinical significance of these effects must be determined in larger, long-term clinical trials.

Research-in-progress Abstract Sample

PLEASE NOTE: Do not include the field names – Purpose and Methods in the body of your abstract.

Title: Compliance with JNC 7 guidelines: treating patients with systematic blood pressure

Purpose: The JNC 7 guidelines recognize that systemic blood pressure (SBP) elevations directly correlate with increased cardiovascular risk. The objective of this study is to determine the extent to which treatment provided to clinic patients with systolic hypertension complies with the JNC 7 guidelines.

Methods: This study will be submitted to the Institutional Review Board for approval. The electronic medical record system will identify patients who have had at least two blood pressure measurements in which systolic blood pressure (SBP) was greater than 139 mmHg and diastolic blood pressure (DBP) was less than 90 mmHg. The following data will be collected: patient age, gender, ethnicity, SBP, DBP, heart rate, physical examination findings, current medications, and reported adverse medication events. If available, results of renal and hepatic function tests and electrocardiograms will be collected. Provider documentation will be reviewed to determine if reasons for non-compliance with JNC 7 guidelines are documented. All data will be recorded without patient identifiers and maintained confidentially. Average SBP and DBP will be calculated. Data from patients with an average SBP of greater than 139 mmHg and an average DBP of less than 90 mmHg will be reviewed by a team of clinicians to rate compliance of treatment with the JNC 7 guidelines. The reviewers will rate each patient's care as compliant with JNC 7, noncompliant with JNC 7 but clinically appropriate, or noncompliant with JNC 7.

Results: N/A

Conclusions: N/A

Case Report Abstract - Sample

PLEASE NOTE: Do not include the field name “Case Report” in the body of your abstract. *The entire abstract is entered in the Case Report Field.*

Title: Potential risk of transdermal alcohol application in patients on warfarin

Case Report: This case series illustrates the potential risk of transdermal alcohol application in patients on warfarin. Patient 1 is being treated with warfarin for heart failure. The patient has a goal INR between 2 and 3 and has had therapeutic INRs at the last twenty-two clinic visits. He presented to clinic with an INR of 4.2. He denied symptoms of heart failure exacerbation, changes in diet, or changes in medications. The patient reported that he had been applying rubbing alcohol to a back injury. At this visit, patient was instructed to discontinue rubbing alcohol, hold two doses of warfarin, and then resume his current warfarin regimen. He returned to clinic 4 weeks later and his INR was 2.3. His INR remained in the therapeutic range for the next 3 follow-up visits. Patient 2 has been prescribed warfarin secondary to an atrial valve replacement and has a goal INR range of 2 to 3. After 6 consecutive therapeutic visits, the patient presented with an INR of 3.2. She denied medication or diet changes, but reported that she had applied rubbing alcohol to sore legs several days prior to the clinic visit. At this visit she was told to discontinue the rubbing alcohol, hold one dose of warfarin, and then resume her previous regimen. The patient returned to clinic 4 weeks later and her INR was 1.8. Patient’s INR remained in the therapeutic range for the next 5 visits. Patient 3 is being treated with warfarin for recurrent venous thromboembolism (VTE) and protein S deficiency. Her therapeutic INR range is 3.0 to 3.5 due to recurrent VTE despite therapeutic INR levels. Her INR in clinic was 4.3 following a recent dose increase of her warfarin. She reported that she had been using 4 ounces of hand sanitizer daily. She was asked to hold her warfarin dose that night, and then resume her current regimen. She returned to clinic 7 days later and her INR was 3.7. Despite being counselled on the risk associated with the alcohol-based hand sanitizer, she continued to use approximately 4 ounces daily. Over the next 2 months the patient’s INR fluctuated greatly with all but one INR in the suprathreshold range. The patient finally discontinued use of the instant hand sanitizer and her INR fell to 2.6. Although the patient’s INR was never completely stable the 2 months following discontinuation of the hand sanitizer, the INR fluctuations were more predictable. As this case series suggests, the application of transdermal alcohol has the possibility to affect INRs in patients being treated with warfarin. Although more study is needed to further elucidate this interaction, it is important for providers to inquire about the topical application of alcohol and alcohol-containing products.

Methods: N/A

Results: N/A

Conclusions: N/A